长药控股被立案，股民索赔可期

Core Viewpoint - Changjiang Pharmaceutical Holdings Co., Ltd. is under investigation by the China Securities Regulatory Commission (CSRC) for suspected false reporting of financial data, which may lead to civil compensation claims from affected investors [1][2]. Summary by Relevant Sections Company Investigation - The CSRC has decided to investigate Changjiang Pharmaceutical due to allegations of false financial reporting, which violates the Securities Law of the People's Republic of China [1]. - The investigation could result in civil liability for the company, its major shareholders, and executives if investors suffer losses due to these alleged misrepresentations [1]. Investor Compensation - A lawyer from Shanghai Hanlian Law Firm is collecting claims from investors who purchased securities of Changjiang Pharmaceutical before November 7, 2025, and either sold or continued to hold them after this date [1]. - The conditions for compensation claims will be adjusted based on the conclusions of the CSRC's administrative penalties and the final court rulings regarding the legal aspects of the claims [1][2]. Legal Process and Requirements - Investors are advised that while they can file lawsuits directly, the lack of an administrative penalty decision may increase the risk of losing such cases [2]. - The progress of civil compensation lawsuits may be affected by the company's potential delisting or bankruptcy proceedings [2]. - Required materials for investors to register for compensation include a copy of their ID, original securities account information, and transaction records [2].